Skip to main content

Patients as Research Partners

Integrated patient engagement model

CCTG uses an integrated patient engagement model that includes the patient voice in all aspects of cancer clinical trial development. A Patient Representative is not only involved in answering the scientific questions that clinical trials ask, they play an essential role on CCTG’s national disease site committee as participating members who contribute to the development and delivery of the cancer research questions. Patient Representatives ensure that patient centred outcomes included in CCTG cancer clinical trials.

A Current Oncology publication outlining the incorporation of patient engagement in the development of clinical trial at CCTG: Integrating Patient Centred Research in the Canadian Cancer Trials Group

Patient-oriented research refers to research that engages patients as partners, focuses on patient-identified priorities and improves patient outcomes. This research, conducted by multidisciplinary teams in partnership with stakeholders, aims to apply the knowledge generated to improve health care systems and practices. – - Michael Smith Foundation for Health Research

Patient engagement in clinical trail research is two-fold:

  1. Trial Participant – the human participant in the trial
  2. Patient Representative – developing and delivering the research question, ensuring: patient feasibility, outcomes that matter to patients

There are several touch points where a Patient Representative provides input as members of Scientific, Oversight and Support Committees. They are actively involved at key junctures of the CCTG Clinical Trial life cycle: Development, Review/Approval, Protocol and Consent Development, Accrual and Data Collection and at the time of Permanent Closure.

CCTG Recruiting for a Patient Representative Volunteer Role

CCTG is currently seeking applications for a Patient Representative for the Hematology Disease Site Committee

More >>
David McMullen CCTG patient rep

CCTG Patient Representative David McMullen honoured with 2023 CCRA award

The Canadian Cancer Research Alliance (CCRA) announced the recipients of its biennial awards, recognizing significant contributions to cancer research in Canada.

More >>
Dan Renouf and Gayl

Improving survival for people with pancreatic cancer

Stories of research impact, CCS Research Impact Report. An international clinical trial has changed the way doctors treat pancreatic cancer around the world.

More >>
CCTG HD12 a hematology trial investigating targeted therapy for early-stage Hodgkin lymphoma opens in Canada

CCTG HD12 a hematology trial investigating targeted therapy for early-stage Hodgkin lymphoma opens in Canada

Researchers will compare the usual treatment for Hodgkin lymphoma, with a new treatment that takes the standard combination drug treatment replacing one of the drugs with brentuximab vedotin that may be more effective and cause fewer side effects for patients.

More >>